NCT03586024 2021-05-07
Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas
Abramson Cancer Center at Penn Medicine
Phase 1/2 Withdrawn
Abramson Cancer Center at Penn Medicine
Western Regional Medical Center